Latest news with #Windtree
Yahoo
23-07-2025
- Business
- Yahoo
BNB Chain News: BNB Hits ATH as Treasury Companies Expand
TL;DR: Altcoin rally: BNB sector hits ATH mcap, +$24.4B weekly. BNB up 14.1%; ecosystem tokens surge, TVL +9.4%, leaders include $SPK & $SLP. Key news: Nano Labs & Windtree treasuries; DIA partnerships; L1 upgrade plans. Bitcoin's dominance is breaking down, sending altcoins soaring. With the CMC Crypto Fear and Greed Index now squarely in the greed category, it's safe to say bullish sentiment has returned. With that in mind, let's see how the BNB Chain sector shaped up this week. BNB Chain Market Recap The BNB Chain sector is on fire, with an across-the-board pump sending its market capitalization (mcap) to an all-time high (ATH). More than $24.4 billion was added to the sector in one of the best weeks on record. Much of this growth is attributed to the standout performance of BNB, which added 14.1% this week and briefly tapped a new ATH of $804. A wave of green was also seen throughout the BNB Chain ecosystem, with some of the best-performing BEP-20 assets adding upwards of 40% week-on-week. This week's best performers and their likely catalysts (if known) include: Spark (SPK): +250.8% (spike in staking due to Ignition Airdrop Phase 2) DIA (DIA): +122.9% (back-to-back partnership announcements with Hydration & Plume) Smooth Love Potion (SLP): +65% (unclear catalyst) Tagger (TAG): +54.1% (investment from BNB Chain Incentive Program) Caldera (ERA): +46.1% (multi-exchange listing, incl. Binance and Coinbase) That said, a handful of laggards failed to benefit from the pump. This week's worst performers include: Chintai (CHEX): -25.8% Banana For Scale (BANANAS31): -14.2% 1inch network (1INCH): -12.1% The BNB Chain platform continues to compare favorably with competing L1s. Per data from Artemis, it leads the competition in terms of daily transaction counts (edging out Solana when discounting vote transactions) as well as on-chain trading volume—regularly clocking in upwards of $9 billion in daily DEX volume. When it comes to daily active addresses and stablecoin transfer volume, it's neck-and-neck with TRON. Source: DefiLlama Overall, the platform grew its TVL by 9.4% this week, with a significant uptick in Binance Staked ETH deposits. BNB Chain News Roundup The recent bullish momentum was underpinned by a wave of positive developments and updates, helping to improve sentiment. Some of this week's most significant updates include: Nano Labs Lifts BNB Reserve to 120K Tokens: The Hong Kong chipmaker expanded its strategic stash to 120,000 BNB (~$90M) and said it will upgrade its BNB reserve strategy, reinforcing its long‑term pivot into Web3 infrastructure. Windtree Therapeutics Plans Up to $200M BNB Treasury: Windtree unveiled a corporate BNB reserve strategy targeting $200M, positioning itself as a major institutional holder and aligning with Build & Build Corp's accumulation push. DIA Links Up With Hydration & Plume: On July 21 and 22, DIA announced integrations with Hydration (Polkadot lending) and Plume (RWA rollup), supplying source-level oracle feeds to both. The move helps to broaden cross-chain data pipes and potential liquidity routes for BNB Chain projects. BNB Chain Teases Ultra-Fast Private L1: A recent blog post outlined plans for several upgrades to BNB Chain, aiming to deliver a next‑gen layer 1: sub‑150 ms finality, 20K+ TPS, Rust client, 10x gas limit, and native privacy. >> That's all for this update. Check in next week for more BNB Chain updates and analyses.
Yahoo
23-07-2025
- Business
- Yahoo
Kraken to Support Biotech Firm Windtree's $200M BNB Treasury Play
Nasdaq-listed biotech firm Windtree Therapeutics has entered into a strategic partnership with crypto exchange Kraken to manage its BNB-focused crypto treasury program, the companies announced Tuesday. The deal will see Kraken handle custody, trading and over-the-counter (OTC) execution of BNB assets for Windtree. So far $60 million has been raised, and another $140 million could be on the cards for the BNB treasury strategy, so potentially a $200 million deal, a Kraken representative said via email. Crypto treasury plays are all rage right now. Windtree says this is the first treasury strategy focused on BNB, the native asset of the Binance Smart Chain. BNB currently ranks among the top five cryptocurrencies by market cap and sees over $2 billion in daily trading volume. Kraken, which serves both institutional and retail clients, will offer Windtree access to secure wallets, deep liquidity, and large-scale execution services. 'We're enabling them to navigate the Binance ecosystem with confidence,' said David Olsson, Kraken's global head of institutional client solutions. BNB is used to pay fees and interact with applications on Binance Smart Chain, which hosts thousands of decentralized apps. By using Kraken's infrastructure, Windtree aims to create a pipeline between traditional shareholders and a DeFi ecosystem that's typically out of reach for U.S. investors. The final agreement will be signed following shareholder and regulatory approval. Sign in to access your portfolio
Business Insider
16-07-2025
- Business
- Business Insider
Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions
WARRINGTON, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ('Windtree' or the 'Company') (NasdaqCM: WINT) is excited to announce it has entered into a $60 million securities purchase agreement led by Build and Build Corp, with the potential for up to an additional $140 million in gross proceeds in future subscriptions, for total subscriptions of up to $200 million. The proceeds, expected to be in the form of cash, shares of Osprey BNB Chain Trust and BNB, from this financing, upon closing, is to be primarily used to launch a BNB crypto treasury strategy and purchase BNB, positioning Windtree as a leader in the BNB digital asset . Subject to shareholder approval and the satisfaction of other closing conditions, Windtree will become the first NASDAQ-listed company offering direct exposure to the BNB token, the fifth-largest blockchain by market capitalization (over $95 billion). This strategy addresses a critical need for retail and institutional investors seeking regulated access to the Binance ecosystem. This transaction is expected to establish a robust BNB Crypto Treasury Strategy, including custody, security and yield generation, positioning the Company as a pioneer in the BNB and Binance Ecosystem. Build and Build Corp's involvement speaks to its confidence in Windtree's vision to become a leader in BNB, driving transformative opportunities within the rapidly evolving digital asset landscape. "We are thrilled to propose a groundbreaking BNB strategy to the U.S. market," said Patrick Horsman, CFA, Director of Build & Build Corp. "This innovative solution will offer investors targeted exposure to Binance and BNB, addressing what we believe to be a critical gap in the U.S. investment landscape." The Binance Ecosystem is a robust network of products and services anchored by the world's largest cryptocurrency exchange. BNB is a leading cryptocurrency with average daily trading volumes of over $2 billion, making it the largest and most liquid crypto exchange token globally. Additionally, the Binance Smart Chain, ('BSC') supports fast, low-cost transactions and a thriving decentralized finance ('DeFi') ecosystem with thousands of dApps and millions of users. Binance's ecosystem maintains dominant market share in Asia, and the Company expects that it is poised for substantial growth globally and in U.S. markets. "Today marks a pivotal moment for Windtree," said Jed Latkin, Chief Executive Officer of Windtree. "This transaction secures up to $200 million from institutional investors, offering our shareholders a unique opportunity to gain exposure to a BNB-focused crypto treasury strategy." This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a diversified company with several divisions, including a cryptocurrency treasury strategy and two promising therapeutic pipelines for which the Company is actively looking for long-term development partners. About Build and Build Corp Build and Build Corp is a dynamic company established by Patrick Horsman, Joshua Kruger, and Johnathan Pasch, who together bring over 43 years of expertise in hedge funds and digital asset management. The company is backed by prominent investors, including Off The Chain Capital, Kraken, Galaxy, and Silvermine, supporting its mission to deliver innovative solutions in the financial and digital asset sectors. Forward Looking Statements The Company may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'proposed,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, among other things: risks related to obtaining shareholder approval for the Build and Build Corp transaction and satisfying the other conditions necessary to consummate the transaction and related transactions, which cannot be assured; the Company's risks and uncertainties associated with the success and advancement of its product candidates; the Company's ability to manage costs and execute on its operational and budget plans; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to regulatory requirements; risks related to the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates, if approved; the impacts of political unrest, including as a result of geopolitical tension, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company's operations, including through disruption in supply chain or access to potential international clinical trial sites. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Business Insider
04-06-2025
- Business
- Business Insider
Windtree Therapeutics announces plan for cryptocurrency treasury policy
Windtree Therapeutics (WINT) announced that its board has agreed that the company will create a cryptocurrency policy that will allow the company to accept cryptocurrency as an option for payment and also allow the company to hold the cryptocurrency as an asset. The company's cryptocurrency policy is intended to align with innovative digital commerce trends where millions of people hold cryptocurrency. If a payment is made to the company with cryptocurrency in its revenue generating business, it can be held long term as a potential strategic asset. 'Windtree is executing our new corporate strategy to become a revenue generating company and we are in discussions with several groups that focus on Bitcoin and other cryptocurrencies as an option for payment. These companies are interested in furthering a treasury strategy in conjunction with Windtree and its current diversified operations base. Our Company can also hold the cryptocurrency as an asset,' said Jed Latkin, CEO of Windtree. 'Our Board is supportive of this opportunity and our development of a cryptocurrency policy which we expect to be completed in the near term.' Confident Investing Starts Here:
Yahoo
22-05-2025
- Business
- Yahoo
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025
Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock Phase 3 program WARRINGTON, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ('Windtree' or the 'Company') (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue-generating company and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it is targeting the planned interim analysis results for the istaroxime cardiogenic shock SEISMiC SCAI Stage C Phase 2 study (the 'SEISMiC C Study') for July 2025. The SEISMiC C Study is a global trial including sites in the U.S., Europe and Latin America. It is a placebo-controlled, double-blinded study with istaroxime being added to current standard of care, including inotropes or vasopressors. The effect of istaroxime in addition to these therapies will be assessed for six hours followed by the ability for istaroxime to allow reduction in the other inotropes and vasopressors based on the patient's condition. The primary endpoint of the study is the systolic blood pressure ('SBP') profile over the first six hours of treatment. Other key study measurements include various measures of cardiac function, SBP changes at specified timepoints, the vasopressor-inotrope score, avoidance of progression to SCAI Stage D or E cardiogenic shock and need for mechanical cardiac support, time to treatment failure, arrhythmia assessments, days alive and out of the hospital through day 30, physiologic measures (e.g., cardiac index) and length of stay in the intensive care unit and hospital. 'The interim data from the SEISMiC C Study are very important as we continue to evaluate the profile of istaroxime in more seriously ill patients with cardiogenic shock due to heart failure. The data from the first 20 patients will provide an initial assessment of the ability of istaroxime to show the same kind of physiological impact on top of standard of care to what has been seen in the previous studies in SCAI Stage B cardiogenic shock, as well as the emerging safety profile in this population,' said Dr. Steve Simonson, Chief Medical Officer and Senior Vice President of Windtree Therapeutics. 'Completion of the SEISMiC C Study is an important milestone to move steadily toward Phase 3 with istaroxime in cardiogenic shock.' About IstaroximeIstaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure demonstrate that istaroxime infused intravenously can significantly improve cardiac function and blood pressure without increasing heart rate or the incidence of clinically significant cardiac rhythm disturbances. About Windtree Therapeutics, Therapeutics, Inc. is a biotechnology company focused on becoming a revenue-generating company and advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree's portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking StatementsThis press release contains statements related to the potential benefits and safety of istaroxime; the clinical development of istaroxime; and our research and development program for treating patients in early cardiogenic shock due to heart failure. Such statements constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'proposed,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, among other things: the Company could lose its deposit on the real estate property discussed above; the Company may fail to acquire such real estate property; the Company's ability to acquire revenue generating subsidiaries; the market's reaction to potential acquisitions by the Company; the Company's ability to secure significant additional capital as and when needed; the Company's ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company's other product candidates, including preclinical oncology candidates; the Company's ability to access the debt or equity markets; the Company's ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company's product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company's efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates, if approved; the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People's Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company's operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company's ability to access the capital markets. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information:Eric Curtisecurtis@
